Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Kraeber Bodéré, Françoise ^a   Bardet, Stephane ^b   Hoefnagel, Cornelis A ^f   Vieira, Maria R ^g   Vuillez, Jean Philippe ^c   Murat, Arnaud ^d   Ferreira, Theresa C ^g   Bardiès, Manuel ^a   Ferrer, Ludovic ^a   Resche, Isabelle ^a   Gautherot, Emmanuel ^e   Rouvier, Eric ^e   Barbet, Jacques ^e   Chatal, Jean François ^a,h  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b François Baclesse Institute   (France)

^c HÔPITAL MICHALLON   (France)

^d HÔTEL DIEU   (France)

^e Immunotech   (France)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g Bone Marrow Transplantation Unit   (Portugal)

^h INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CALCITONIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN; IODINE 131; MONOCLONAL ANTIBODY F6 734; PENTETATE INDIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; BONE MARROW; BONE MARROW TOXICITY; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY; LIVER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SCINTIGRAPHY; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; CARCINOMA, MEDULLARY; FEMALE; HAPTENS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS;

EID: 0032719527     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Knox, S. J. Radioimmunotherapy of the non-Hodgkin's lymphomas. Semin. Radiat. Oncol., 4: 331-341, 1995.
2. Chatal, J. F., and Mahé, M. Therapeutic use of radiolabeled antibodies. In: P. Murray and P. Ell (eds.), Nuclear Medicine in Clinical Diagnosis and Treatment, 2nd ed., pp. 1101-1114. Edinburgh: Churchill Livingstone, 1998.
3. Mach, J. P., Pelegrin, A., and Bucchegger, F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr. Opin. Immunol., 3: 685-693, 1991.
4. Chatal, J. F., Saccavini, J. C., Gestin, J. F., Thedrez, P., Curtet, C., Kremer, M., Guerreau, D., Nolibe, D., Fumoleau, P, and Guillard, Y. Biodistribution of indium-111-labeled OC125 monoclonal antibody intraperitoneally injected into patients, operated for ovarian carcinomas. Cancer Res., 49: 3087-3094, 1989.
5. 2. J. Nucl. Med., 37: 1504-1510, 1996.
6. Marsh, D. J., Learoyd, D. L., and Robinson, B. G. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 5: 407-424, 1995.
7. Schlumberger, M., and Baudin, E. Tumeurs neuro-endocrines. Ann. Endocrinol. 58: 95-99, 1997.
8. Schlumberger, M., Abdelmouene, N., Delisle, M. J., and Couette, J. E., GETC. Treatment of advanced medullary thyroid cancer with an alternating combination of 5FU-streptozocin and 5FU-dacarbazine. Br. J. Cancer. 71: 363s-365s, 1995.
9. Wu, L. T., Averbuch, S. D., Ball, D. W., De Bustros, A., Baylin, S. B., and McGuire, W. P. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer (Phila.), 73: 432-436, 1994,.
10. Lupoli, G., Cascone, E., Arlotta, F., Vitale, G., Celentano, L., Salvatore, M., and Lombardi, G. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant Interferon α-2b and octreotide. Cancer (Phila.), 78: 1114-1118, 1996.
11. Hoefnagel, C. A. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur. J. Nucl. Med., 21: 561-581, 1994.
12. Ishikawa, N., and Hamada, S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br. J. Cancer, 34: 111-115, 1976.
13. Le Doussal, J. M., Martin, M., Gautherot, E., Delaage. M., and Barbet, J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med., 30: 1358-1366, 1989.
14. Le Doussal, J. M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res., 50: 3445-3452, 1990.
15. Barbet, J., Peltier, P., Bardet, S., Vuillez, J. P., Bachelot, I., Denet, S., Olivier, P., Leccia, F., Corcuff, B., Huglo, D., Proye, C., Rouvier, E., Meyer, P., and Chatal J. F. Radioimmunodetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and anti-CEA x anti-DTPA-Indium bispecific antibody. J. Nucl. Med., 39: 1172-1178, 1998.
16. Bardiès, M., Bardet, S., Faivre-Chauvet, A., Peltier, P., Douillard J. Y., Mahé, M., Fiche, M., Lisbona, A., Giacalone, F., Meyer, P., Gautherot, E., Rouvier, E., Barbet, J., and Chatal J. F. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J. Nucl. Med., 37: 1853-1859, 1996.
17. 131I-Lym-1 in patients with B-cell malignancies. Nucl. Med. Commun., 14: 587-595, 1993.
18. Wittes, R. Manual of Oncological Therapeutics, pp. 446-448. Philadelphia: Lippincott, 1989.
19. Le Doussal, J. M., Chetanneau, A., Gruaz-Guyon, A., Martin, M., Gautherot, E., Lehur, P. A., Chatal, J. F., Delaage, M., and Barbet, J. Bispecific monoclonal antibody mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. Nucl. Med., 10: 1662-1671, 1993.
20. Hosono, M., Hosono, M., Kraeber-Bodéré, F., Devys, A., Thédrez, P., Fiche, M., Gautherot, E., Barbet, J., and Chatal, J. F. Biodistribution and dosimetry study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J. Nucl. Med., 39: 1608-1613, 1998.
21. 131I-labeled anti-CEA antibodies. J. Nucl. Med., 37: 905-911, 1996.
22. Devys, A., Thédrez, P., Gautherot, E., Faivre-Chauvet, A., Sai-Maurel, C., Rouvier, E., Auget, J. L., Barbet, J., and Chatal, J. F. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. Int. J. Cancer. 67: 883-891, 1996.
23. Behr, T., Sharkey, R. M., Juweid, M., Dunn, R., Vagg, R. C., Ying, Z., Zhang, C. H., Swayne, L., Vardi, Y. C.. Siegel, J., and Goldenberg, D. M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med., 38: 858-870, 1997.
24. Welt, S., Divgi, C. R., Kemeny, N., Finn, R. D., Scott, A. M., Graham, M., Germain, J. S., Richards, E. C., Larson, S. M., Oettgen, H. F., and Old, L. J. Phase I/II study of iodine-131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12: 1561-1571, 1994.
25. Ychou, M., Pelegrin, A., Faurous, P., Robert, B., Saccavini, J. C., Guerreau, D., Rossi, J. F., Fabbro, M., Buccheger, F., Mach, J. P., and Artus, J. C. Phase I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer, 75: 615-619, 1998.
26. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., Kostakoglu, L., Schlom, J., and Larson, S. M. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med., 36: 586-592, 1995.
27. Behr T. M., Sharkey R. M., Juweid M. E., Dunn, R. M., Ying, Z., Zhang, C. H., Siegel, J. A., Gold D. V., and Goldenberg, D. M. Factors influencing the pharmakocinetics, dosimetry and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res., 56: 1805-1816, 1996.
28. Kraeber-Bodéré, F., Faivre-Chauvet, A., Sai-Maurel, C., Gautherot, E., Fiche, M., Campion, L., Le Boterff, J., Barbet, J., Chatal, J. F., and Thédrez, P. Comparative toxicity and efficacy of one- and two-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J. Nucl. Med., 40: 198-204, 1999.
29. Schlumberger, M. Challeton, C., De Vathaire, F., Travagli, J. P., Gardet, P., Lumbroso, J. D., Francese, C., Fontaine, F., Ricard, M., and Parmentier, C. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med., 37: 598-605, 1996.
30. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641-2658, 1988.
31. Brown, J. M., and Giacca, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
32. Thomas, S. R., Maxon, H. R., Kereiakes, J. G., and Saenger, E. L. Quantitative external counting techniques enabling improved diagnostic and therapy decisions in patients with well-differentiated thyroid cancer. Radiology, 122: 731-737, 1977.
33. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Ying, Z., Zhang, C. H., Siegel, J. A., and Goldenberg, D. M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J. Nucl. Med., 38: 409-418, 1997.
34. Mc Ewan, A. J. B., Amyotte, G., Morin, C., McGowan, D. G., Fields, A. L. A., and Smylie, M. High dose I-131 mIBG therapy in patients with metastatic carcinoid tumors. J. Nucl. Med., 37: 237P, 1996.
35. Behr, T. M., Wulst, E., Radetsky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-FrΣnk. M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresitant tumor type. Cancer Res., 57: 5309-5319, 1997.
36. DeNardo, S. J., Kukis, D. L., Kroger, L. A., O' Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., and DeNardo, G. L. Synergy of Taxol with yttrium-90-ChL6 radioimmunotherapy: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. USA, 94: 4000-4004, 1997.